Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Tuesday, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced two tools to streamline the drug development process for pharmaceutical and biotech companies.
星期二，Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) 宣佈了兩種工具，以簡化藥品研發流程，適用於製藥和生物技術公司。
Building on its partnership with Alphabet Inc's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google Cloud, Ginkgo introduced a protein large language model (LLM) and a model API, both designed to accelerate medicine development by leveraging AI and proprietary biological data.
在與Alphabet Inc的（NASDAQ:GOOG）（NASDAQ:GOOGL）Google Cloud 的合作基礎上，Ginkgo引入了蛋白質大型語言模型（LLM）和模型API，旨在通過利用人工智能和專有生物數據加速藥物開發。
These offerings aim to simplify and enhance how researchers and companies discover new therapeutics.
這些產品旨在簡化和增強研究人員和公司發現新型治療方法的過程。
Researchers at Google DeepMind have developed AlphaFold 3, an new artificial intelligence (AI) model.
Google DeepMind的研究人員開發了AlphaFold 3，一個新的人工智能（AI）模型。
AlphaFold 3 can predict the structure and interactions of biological molecules. This includes proteins, DNA RNA, and small molecules that could function as drugs.
AlphaFold 3可以預測生物分子的結構和相互作用。這包括蛋白質、DNA、RNA和可能作爲藥物的小分子。
The new protein LLM, developed in collaboration with Google Cloud Consulting and built on Vertex AI, offers powerful insights derived from Ginkgo's private data to individual researchers and enterprise companies.
這個由Ginkgo和Google Cloud Consulting合作開發的新蛋白質LLm是基於Vertex AI 構建的，爲個體研究者和企業公司提供了強大的從Ginkgo私有數據中獲取的見識。
The model can help identify new therapeutic targets by analyzing protein structures and interactions, speeding up the discovery and development of life-saving medicines.
該模型可以通過分析蛋白質結構和相互作用來幫助識別新的治療目標，加快了挖掘和開發拯救生命藥物的過程。
This tool is expected to revolutionize drug development pipelines, optimizing the process from lead identification to final approval.
這個工具預計將革新藥物開發流程，優化從首選藥物發現到最終批准的過程。
In addition to the LLM, Ginkgo has launched its model API, an accessible and affordable tool aimed at providing machine learning scientists with AI models trained on Ginkgo's proprietary protein and DNA datasets.
除了LLM，Ginkgo還推出了其模型API，這是一個可訪問和實惠的工具，旨在爲機器學習科學家提供在Ginkgo的專有蛋白質和DNA數據集上訓練的AI模型。
This API is available on Ginkgo's website, with plans for enterprise access through Google Cloud's Vertex AI Model Garden.
該API可在Ginkgo的網站上獲得，並計劃通過Google Cloud的Vertex AI模型庫提供企業訪問權限。
The API enables users to generate insights through advanced methods like masked language modeling and embedding calculations.
該API使用戶能夠通過遮蔽語言建模和嵌入計算等先進方法生成見解。
Ankit Gupta highlighted that predictions on protein sequences could be obtained for as little as $0.18 per million tokens, allowing researchers to scale their experiments without incurring high costs.
Ankit Gupta指出，蛋白質序列的預測只需每百萬個令牌0.18美元，使研究人員能夠以較低的成本擴大實驗規模。
Ginkgo plans to release more models over the next year, broadening the API's capabilities and expanding its suite of tools to tackle complex drug discovery, synthetic biology, and genomics challenges.
Ginkgo計劃在未來一年推出更多模型，擴展API的功能，並擴大工具套件，以應對複雜的藥物發現、合成生物學和基因組學挑戰。
Price Action: DNA stock is up 11.60% at $6.95 at the last check on Tuesday.
價格走勢：DNA股票在週二最後一次檢查時上漲11.60%，至6.95美元。
- Amazon's Leaner Structure and AI Chip Partnership with Intel Could Boost Growth: BofA Analyst.
- 亞馬遜與英特爾的精簡架構和AI芯片合作可能會提振增長：BofA分析師。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。